Transcatheter mitral valve repair using the Cardioband® system: Histopathological insights in device ingrowth and biocompatibility.
Cardioband
biocompatibility
mitral annuloplasty
mitral regurgitation
tissue reaction
transcatheter mitral valve repair
Journal
Journal of cardiac surgery
ISSN: 1540-8191
Titre abrégé: J Card Surg
Pays: United States
ID NLM: 8908809
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
19
06
2021
accepted:
23
06
2021
pubmed:
27
7
2021
medline:
14
9
2021
entrez:
26
7
2021
Statut:
ppublish
Résumé
Surgical implantation of a complete or incomplete ring to reduce the valve annulus and improve leaflet coaptation is the mainstay of mitral valve surgery. The Cardioband® system (Edwards Lifesciences) was designed to address the pathophysiological mechanism of annular dilatation through a catheter-based approach. We present the histopathological workup of a Cardioband® device, which had been implanted 21 months earlier in a 34-year-old male with ischemic cardiomyopathy. Device examination demonstrate a well-positioned and securely anchored device. The described tissue reactions may have an impact on choice of device and timing in case of re-do surgery.
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
3869-3871Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Miller M, Thourani VH, Whisenant B. The Cardioband transcatheter annular reduction system. Ann Cardiothorac Surg. 2018;7(6):741-747. https://doi.org/10.21037/acs.2018.10.10
Sigler M, Paul T, Grabitz RG. Biocompatibility screening in cardiovascular implants. Z Kardiol. 2005;94(6):383-391. https://doi.org/10.1007/s00392-005-0231-4